Selection of COVID-19 specific therapy in patients who have severe infection requiring O₂ supplementation

This algorithm covers selection of COVID-19-specific therapy only. Refer to other UpToDate content for discussion of other management issues, including management of hypoxia, prevention of thromboembolism, and management of other complications. The approach to COVID-19-specific therapy in individuals who have no oxygen requirement or who are seen in the outpatient setting is also covered elsewhere.

ECMO: extracorporeal membrane oxygenation; ICU: intensive care unit; CRP: C-reactive protein.

* If dexamethasone is unavailable, other glucocorticoids at equivalent doses are reasonable alternatives.

¶ For those who are stably on minimal supplemental oxygen (eg, 1 to 2 L/min), it is reasonable to forgo dexamethasone and use remdesivir alone, particularly in patients who are immunocompromised and within 10 days of illness onset.

Δ The clinical benefit of remdesivir is uncertain in patients who need support beyond low-flow oxygen, but it is reasonable to use it in those on high-flow or noninvasive ventilation, particularly if they are immunocompromised and receiving immunomodulatory agents for COVID-19.

◊ Tocilizumab and baricitinib should be used with caution in immunocompromised patients, among whom the safety of further immune modulation with such agents is uncertain.

Graphic 134578 Version 5.0

خرید پکیج

Selection of COVID-19 specific therapy in patients who have severe infection requiring O2 supplementation

Selection of COVID-19 specific therapy in patients who have severe infection requiring O₂ supplementation